← board
GRML
distress 5/10 · elevated risk$0.23+5%today-83% from 52w high
Revenue
pre-revenue
Liquidity
$10M
Runway
1.1 yrs
Shares 1y
+98%
Price & events
-31.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+5.0%
1D
+33.9%
1W
-9.0%
1M
-48.1%
3M
-28.5%
6M
-81.7%
1Y
-82.6%
2Y
—
5Y
-97.6%
All
Overview
- Market Cap
- $28.25M
- Volume
- 7.68M
- 52 Week Range
- $0.17 – $1.36
- Total Shares
- 121.24M
- Float Shares
- 100.34M
- Short %
- 4.63%
- % Held by Insiders
- 13.72%
- % Held by Institutions
- 6.48%
- RVOL
- 1.11x
- Beta
- 2.52
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2025-08-06partnershipKLTO-202 · Manufacturing and development agreement with AAVnerGene using AAVone platformSEC 8-K
- 2024-09-24partnershipDr. Robert Langer, co-founder of Moderna, joined Scientific Advisory Board.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 121,238,660 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $3 (+973% upside) · 1 analysts
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.